Cargando…

The impact of disease-modifying therapies on immunoglobulin blood levels in patients with multiple sclerosis: a retrospective cross-sectional study

BACKGROUND: Although disease-modifying therapies (DMTs) in multiple sclerosis (MS) are known to target the immune system, mechanisms of action, efficacy, safety, and tolerability profiles differ. The long-term impact of DMTs on the immune system and its relation to infectious complications is still...

Descripción completa

Detalles Bibliográficos
Autores principales:	Klein, Ana, Flaskamp, Martina, Berthele, Achim, Held, Friederike, Muratovic, Harisa, Hemmer, Bernhard
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2023
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10126592/ https://www.ncbi.nlm.nih.gov/pubmed/37114068 http://dx.doi.org/10.1177/17562864231162661

Ejemplares similares

Frequency of myelin oligodendrocyte glycoprotein antibodies in a large cohort of neurological patients
por: Held, Friederike, et al.
Publicado: (2021)

Drug Treatment of Neuromyelitis Optica Spectrum Disorders: Out with the Old, in with the New?
por: Held, Friederike, et al.
Publicado: (2021)

Association of obesity with disease outcome in multiple sclerosis
por: Lutfullin, Isabel, et al.
Publicado: (2023)

Ocrelizumab-assoziierte schwere Neutropenie: eine unterschätzte Komplikation der Therapie mit CD20-Antikörpern bei Multipler Sklerose?
por: Hess, Felix, et al.
Publicado: (2023)

Percentage brain volume change in multiple sclerosis mainly reflects white matter and cortical volume
por: Lauerer, Markus, et al.
Publicado: (2022)

Association of the retinal vasculature, intrathecal immunity, and disability in multiple sclerosis
por: Noll, Christina, et al.
Publicado: (2022)

Prognostic value of white matter lesion shrinking in early multiple sclerosis: An intuitive or naïve notion?
por: Pongratz, Viola, et al.
Publicado: (2019)

Controversy on the treatment of multiple sclerosis and related disorders: positional statement of the expert panel in charge of the 2021 DGN Guideline on diagnosis and treatment of multiple sclerosis, neuromyelitis optica spectrum diseases and MOG-IgG-associated disorders
por: Bayas, A., et al.
Publicado: (2021)

Gray matter atrophy in relapsing-remitting multiple sclerosis is associated with white matter lesions in connecting fibers
por: Bussas, Matthias, et al.
Publicado: (2021)

Multiple sclerosis lesions and atrophy in the spinal cord: Distribution across vertebral levels and correlation with disability
por: Bussas, Matthias, et al.
Publicado: (2022)

Dynamics of Retinal Vessel Loss After Acute Optic Neuritis in Patients With Relapsing Multiple Sclerosis
por: Aly, Lilian, et al.
Publicado: (2022)

Somatosensory evoked potentials and magnetic resonance imaging of the central nervous system in early multiple sclerosis
por: Wuschek, Alexander, et al.
Publicado: (2022)

Lesion location across diagnostic regions in multiple sclerosis
por: Pongratz, Viola, et al.
Publicado: (2023)

Failure of alemtuzumab as a rescue in a NMOSD patient treated with rituximab
por: Kowarik, Markus C., et al.
Publicado: (2016)

Cortical pathology in multiple sclerosis detected by the T1/T2‐weighted ratio from routine magnetic resonance imaging
por: Righart, Ruthger, et al.
Publicado: (2017)

HLA-DRB1(∗)0401 and HLA-DRB1(∗)0408 Are Strongly Associated with the Development of Antibodies against Interferon-β Therapy in Multiple Sclerosis
por: Hoffmann, Steve, et al.
Publicado: (2008)

Genetic Variation in WNT9B Increases Relapse Hazard in Multiple Sclerosis
por: Vandebergh, Marijne, et al.
Publicado: (2021)

Factors associated with depressive mood at the onset of multiple sclerosis - an analysis of 781 patients of the German NationMS cohort
por: Salmen, Anke, et al.
Publicado: (2023)

Update on immunopathogenesis and immunotherapy in multiple sclerosis
por: Selter, Rebecca C, et al.
Publicado: (2013)

Ethical use of off-label disease-modifying therapies for multiple sclerosis
por: Laurson-Doube, Joanna, et al.
Publicado: (2021)

Retrospective cohort study to devise a treatment decision score predicting adverse 24-month radiological activity in early multiple sclerosis
por: Hapfelmeier, Alexander, et al.
Publicado: (2023)

T1-Weighted Intensity Increase After a Single Administration of a Linear Gadolinium-Based Contrast Agent in Multiple Sclerosis
por: Grahl, S., et al.
Publicado: (2020)

Differential Effects of Fingolimod and Natalizumab on Magnetic Resonance Imaging Measures in Relapsing–Remitting Multiple Sclerosis
por: Grahl, S., et al.
Publicado: (2021)

New immunopathologic insights into multiple sclerosis
por: Hemmer, Bernhard, et al.
Publicado: (2003)

Review of the pharmacoeconomics of early treatment of multiple sclerosis using interferon beta
por: Castrop, Florian, et al.
Publicado: (2013)

Association of pregnancies with risk of multiple sclerosis
por: Gasperi, Christiane, et al.
Publicado: (2022)

Vaccination frequency in people newly diagnosed with multiple sclerosis
por: Darvishi, Sonia, et al.
Publicado: (2023)

CSF parameters associated with early MRI activity in patients with MS
por: Klein, Ana, et al.
Publicado: (2019)

CXCL13 is the major determinant for B cell recruitment to the CSF during neuroinflammation
por: Kowarik, Markus C, et al.
Publicado: (2012)

Aggressive multiple sclerosis (2): Treatment
por: Arrambide, Georgina, et al.
Publicado: (2020)

From Leflunomide to Teriflunomide: Drug Development and Immuno-suppressive Oral Drugs in the Treatment of Multiple Sclerosis
por: Aly, Lilian, et al.
Publicado: (2017)

Reduced serum immunoglobulin G concentrations in multiple sclerosis: prevalence and association with disease-modifying therapy and disease course
por: Zoehner, Greta, et al.
Publicado: (2019)

Impact of COVID-19 on multiple sclerosis care and management: Results from the European Committee for Treatment and Research in Multiple Sclerosis survey
por: Portaccio, Emilio, et al.
Publicado: (2021)

Simultaneous Quantification and Speciation of Trace Metals in Paired Serum and CSF Samples by Size Exclusion Chromatography–Inductively Coupled Plasma–Dynamic Reaction Cell–Mass Spectrometry (SEC-DRC-ICP-MS)
por: Michalke, Bernhard, et al.
Publicado: (2021)

CNS demyelinating events in primary Sjögren's syndrome: A single-center case series on the clinical phenotype
por: Afzali, Ali M., et al.
Publicado: (2023)

Evidence for the Role of B Cells and Immunoglobulins in the Pathogenesis of Multiple Sclerosis
por: Wootla, Bharath, et al.
Publicado: (2011)

Cerebrospinal fluid immunoglobulins in primary progressive multiple sclerosis are pathogenic
por: Wong, Jamie K, et al.
Publicado: (2023)

Differential effects of disease modifying drugs on peripheral blood B cell subsets: A cross sectional study in multiple sclerosis patients treated with interferon-β, glatiramer acetate, dimethyl fumarate, fingolimod or natalizumab
por: Kemmerer, C. L., et al.
Publicado: (2020)

Serum heat shock protein 70 levels as a biomarker for inflammatory processes in multiple sclerosis
por: Lechner, Patricia, et al.
Publicado: (2018)

Cytokine and immune cell profiling in the cerebrospinal fluid of patients with neuro-inflammatory diseases
por: Lepennetier, Gildas, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_nd1shpmee02a3v94onef52omj1